Aprepitant: drug-drug interactions in perspective.

@article{Aapro2010AprepitantDI,
  title={Aprepitant: drug-drug interactions in perspective.},
  author={Matti S. Aapro and Christine M. Walko},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 12},
  pages={2316-23}
}
The implications of chemotherapeutic drug-drug interactions can be serious and thus need to be addressed. This review concerns the potential interactions of the antiemetic aprepitant, a neurokinin-1 receptor antagonist indicated for use (in Europe) in highly emetogenic chemotherapy and moderately emetogenic chemotherapy (MEC) in combination with a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and corticosteroids and (in the United States) in combination with other antiemetic agents, for the… CONTINUE READING